Serum levels of soluble Fas antigen in chronic hepatitis C patients

Journal of Hepatology

Volumn 29, Issue 4, 1998, Pages 517-523

  Iio, Sadaharu ^a   Hayashi, Norio ^a   Mita, Eiji ^a   Ueda, Keiji ^a   Mochizuki, Kiyoshi ^a   Hiramatsu, Naoki ^a   Kanto, Tatsuya ^a   Sasaki, Yutaka ^a   Kasahara, Akinori ^b   Hori, Masatsugu ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Apoptosis; Chronic hepatitis C; Soluble Fas antigen

Indexed keywords

ALANINE AMINOTRANSFERASE; FAS ANTIGEN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS TITRATION;

EID: 0032191653     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80145-1     Document Type: Article

References (33)

1. 1. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo Q-L, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-500.
2. 2. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne, non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
3. 3. Kerr JFR, Cooksley WGE, Searle J, Halliday JW, Halliday WJ, Holder L, et al. The nature of piecemeal necrosis in chronic active hepatitis. Lancet 1979; ii: 827-8.
4. 4. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57.
5. 5. Hayata T, Nakano Y, Yoshizawa K, Sodeyama T, Kiyosawa K. Effect of interferon on intrahepatic human leukocyte antigens and lymphocyte subsets in patients with chronic hepatitis B and C. Hepatology 1991; 13: 1022-8.
6. 6. Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo Q, et al. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus; identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995; 96: 2311-21.
7. 7. Ballardini G, Groff P, Pontisso P, Giostra F, Francesconi R, Lenzi M, et al. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion molecules. Clue to the pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C. J Clin Invest 1995; 95: 2067-75.
8. 8. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytotoxic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650-2.
9. 9. Kägi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-30.
10. 10. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 2333-43.
11. 11. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-78.
12. 12. Hanabuchi S, Koyanagi M, Kawanishi A, Shinohara N, Matsuzawa A, Nishimura Y, et al. Fas and Fas ligand in a general mechanism of T-cell mediated cytotoxicity. Proc Natl Acad Sci USA 1994; 91: 4930-4.
13. 13. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effects of the anti-Fas antibody in mice. Nature 1993; 364: 806-9.
14. 14. Ni R, Tomita Y, Matsuda K, Ichihara A, Ishimura K, Ogasawara J, et al. Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp Cell Res 1994; 215: 332-7.
15. 15. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182: 1223-30.
16. 16. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, et al. Immunohistochemical detection of Fas antigen in liver tissues of patients with chronic hepatitis C. Hepatology 1994; 19: 1354-9.
17. 17. Mita E, Hayashi N, Iio S, Takehara T, Hijioka T, Kasahara A, et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994; 204: 468-74.
18. 18. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, et al. Protection from Fas-mediated apoptosis by soluble form of the Fas molecule. Science 1994; 263: 1759-62.
19. 19. Knipping E, Debatin KM, Stricker K, Heilig B, Eder A, Krammer PH. Identification of soluble APO-1 in supernatants of human B-and T-cell lines and increased serum levels in B-and T-cell leukemias. Blood 1995; 85: 1562-9.
20. 20. Johnson PJ, McFarlane IG. Meeting report: International autoimmune hepatitis group. Hepatology 1993, 18: 998-1005.
21. 21. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
22. 22. Endo S, Inada K, Takakuwa T, Kasai T, Yamada Y, Wakabayashi G, et al. Nitrite/nitrate (NOx) and sFas antigen levels in patients with multiple organ failure. Res Commun Mol Pathol Pharm 1996; 92: 253-6.
23. 23. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor binding proteins purified from human urine: evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990; 265: 1531-6.
24. 24. Josimovic-Alasevic O, Darkop H, Schwartung R, Backe E, Stein H, Diamantstein T. Ki-1(CD30) antigen is released by Ki-1 positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 1989; 19: 157-62.
25. 25. Bjrck P, Braesch-Andersen S, Paulie S. Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40. Immunology 1994; 83: 430-7.
26. 26. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995; 154: 2706-13.
27. 27. Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996; 156: 4622-30.
28. 28. Marinos G, Naoumov NV, Rossol S, Torre F, Wong PYN, Gallati H, et al. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 1995; 108: 1453-63.
29. 29. Thomson AW, Satoh S, Nussler AK, Tamura K, Woo J, Gavaler J, et al. Circulating intercellular adhesion molecule-1 (ICAM-1) in autoimmune liver disease and evidence for the production of ICAM-1 by cytokine-stimulated human hepatocytes. Clin Exp Immunol 1994; 95: 83-90.
30. 30. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995; 14: 1129-35.
31. 31. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997; 3: 409-13.
32. 32. McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren MH. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol 1996; 91: 1516-22.
33. 33. Mochizuki K, Hayashi N, Hiramatsu N, Katayama K, Kawanishi Y, Kasahara A, et al. Fas antigen expression in liver tissue of patients with chronic hepatitis B. J Hepatol 1996; 24: 1-7.